<DOC>
	<DOCNO>NCT00994214</DOCNO>
	<brief_summary>The purpose study assess efficacy repeat subcutaneous ( skin ) injection different dos BIM 23A760 growth hormone insulin-like growth factor-1 level patient acromegaly 6 month treatment .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Repeated Administration BIM 23A760 Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>IGF1 ≥1.3 x upper limit normal ( ULN ) Nadir serum GH concentration ≥0.4 ng/mL oral glucose tolerance test ( OGTT ) Patient must documentation support diagnosis acromegaly , include elevate GH and/or insulinlike growth factor1 ( IGF1 ) level . The patient receive long act somatostatin analogue within 6 month study entry The patient undergone radiotherapy time prior study entry The time pituitary surgery ( ) study entry le 6 week The patient suffers macroadenoma visual field defect due chiasmatic compression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>